1. Home
  2. IMXI vs CELC Comparison

IMXI vs CELC Comparison

Compare IMXI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$15.39

Market Cap

456.2M

Sector

Technology

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$101.35

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMXI
CELC
Founded
1994
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
456.2M
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
IMXI
CELC
Price
$15.39
$101.35
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$16.67
$100.13
AVG Volume (30 Days)
241.4K
980.5K
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$625,123,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.95
N/A
P/E Ratio
$11.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.58
$7.58
52 Week High
$21.41
$112.64

Technical Indicators

Market Signals
Indicator
IMXI
CELC
Relative Strength Index (RSI) 62.97 59.72
Support Level $15.32 $97.27
Resistance Level $15.43 $105.14
Average True Range (ATR) 0.06 5.05
MACD -0.02 -1.40
Stochastic Oscillator 40.91 27.26

Price Performance

Historical Comparison
IMXI
CELC

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: